Hims & Hers Health Stock: Investor and Analyst Perspectives

In-Depth Analysis

### Institutional Investor Activity

Several institutional investors have recently adjusted their positions in Hims & Hers Health (HIMS). Dakota Wealth Management established a new stake, acquiring 7,100 shares valued at approximately $354,000 during the second quarter of 2025. Similarly, Occidental Asset Management LLC made a new investment, purchasing 6,112 shares worth around $305,000 in the same period.

However, not all institutional investors are increasing their positions. Abacus FCF Advisors LLC reduced its holdings by 52.6%, selling 62,147 shares. Despite the sale, Abacus FCF Advisors LLC still holds 55,943 shares of the company's stock, valued at $2,789,000.

Other firms like Geneos Wealth Management Inc., UMB Bank n.a., and Larson Financial Group LLC have also made changes to their positions, reflecting varied confidence levels among institutional investors.

### Insider Trading

Recent insider trading activity reveals significant selling by top executives. CEO Andrew Dudum sold 660,000 shares at an average price of $50.58, totaling $33,382,800. Following this transaction, Dudum directly owns 2,214,769 shares valued at $112,023,016.02. CFO Oluyemi Okupe sold 145,000 shares at an average price of $55.35, amounting to $8,025,750. After the sale, Okupe holds 128,984 shares valued at approximately $7,139,264.40.

These insider sales represent a 22.96% and 52.92% decrease in Dudum and Okupe's positions, respectively. Such large sales by key executives can sometimes signal a lack of confidence in the company's near-term prospects, although there may be various personal financial reasons for these transactions.

### Analyst Ratings and Price Targets

Analyst ratings on Hims & Hers Health are mixed. Citigroup reiterated a \"sell\" rating, while Canaccord Genuity reissued a \"buy\" rating with a $68.00 price objective. Truist Financial dropped their target price from $48.00 to $37.00, maintaining a \"hold\" rating. The consensus among analysts is a \"Reduce\" rating, with an average target price of $38.92.

### Financial Performance

Hims & Hers Health reported its latest quarterly earnings on August 4th, 2025, announcing an EPS of $0.17, which missed the consensus estimate of $0.18 by $0.01. However, the company's revenue for the quarter was $544.83 million, up 72.6% compared to the same quarter last year. The company's return on equity is 26.26%, with a net margin of 9.63%.

### Hims & Hers Health Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care. Founded in 2017 and headquartered in San Francisco, CA, the company aims to provide convenient and affordable access to healthcare services.

Read source article

FAQ

Takeaways

• Monitor institutional investment trends to gauge confidence in HIMS stock.
• Be aware of insider trading activities, particularly sales by key executives, as they may impact stock performance.
• Consider analyst ratings and price targets, but also conduct independent research.
• Evaluate the company's financial performance, including revenue growth and earnings per share, to make informed investment decisions.

Discussion

Do you think Hims & Hers Health will continue to attract institutional investment despite insider selling? Share your thoughts in the comments below!

Share this article with others who need to stay ahead of this trend!

Sources

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.